Replies to post #54254 on NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Tmz is already approved so I take it to mean that study is enough. Not all patients are TMZ responders. If a patient responds to chemotherapy, then long term use makes sense. My point to Senti was that GBM oncologist know how to prescribe chemotherapy. It may have contributed to the Phase I/II results. This study is going to test the sum of the parts, and whether the vaccine induces a significant enough response. I'm not sure if you've seen my last post that also confirms the TMZ long-term findings:

www.ncbi.nlm.nih.gov/pmc/articles/PMC2818769/

An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1

Aggressive treatment with chemo-and radiotherapy has been shown to significantly decrease mortality in patients with classical or mesenchymal subtypes, but has not been shown to significantly alter mortality in the proneural subtypes.

Benefit is derived at more intensive therapy: concurrent chemotherapy and radiation or greater than four cycles of chemotherapy.